Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
95 hedge funds and large institutions have $269M invested in Accelerate Diagnostics in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 9 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
3% more funds holding
Funds holding: 92 → 95 (+3)
7% more call options, than puts
Call options by funds: $2.17M | Put options by funds: $2.03M
4% more capital invested
Capital invested by funds: $259M → $269M (+$9.98M)
0% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$2.55M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.03M |
| 3 |
OCMI
Oaktop Capital Management II
Chatham,
New Jersey
|
+$1.68M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.21M |
| 5 |
Barclays
London,
United Kingdom
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.6M |
| 2 |
MGM
Miura Global Management
New York
|
-$4.02M |
| 3 |
VAM
Visium Asset Management
New York
|
-$2.16M |
| 4 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$1.59M |
| 5 |
Renaissance Technologies
New York
|
-$1.02M |
AXDX Hedge Fund Activity: Q2 2016 in Review
95 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2016, worth a combined $269M — up 3.9% from $259M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AXDX positions and 9 closed out — a net gain of 3 holders — while 31 added to existing stakes and 31 trimmed.
The largest buyer was William Blair & Company, adding an estimated $2.55M. The largest seller was Fidelity Investments, exiting entirely with an estimated $5.6M sold.
- 95 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2016, up from 92 in Q1 2016.
- Funds reported $269M of Accelerate Diagnostics stock for Q2 2016, up 3.9% quarter-over-quarter.
- 12 funds opened new Accelerate Diagnostics positions in Q2 2016 and 9 closed out, a net change of +3 holders.
- The largest Accelerate Diagnostics buyer in Q2 2016 was William Blair & Company, an estimated $2.55M added.
- The largest Accelerate Diagnostics seller in Q2 2016 was Fidelity Investments, an estimated $5.6M sold.
Based on aggregated 13F filings for Q2 2016.